company background image
IMTX

Immatics NasdaqCM:IMTX Stock Report

Last Price

US$8.34

Market Cap

US$635.7m

7D

5.3%

1Y

-10.4%

Updated

05 Feb, 2023

Data

Company Financials +

IMTX Stock Overview

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.

IMTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Immatics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immatics
Historical stock prices
Current Share PriceUS$8.34
52 Week HighUS$13.60
52 Week LowUS$5.75
Beta0.56
1 Month Change-11.65%
3 Month Change-20.11%
1 Year Change-10.42%
3 Year Changen/a
5 Year Changen/a
Change since IPO-13.13%

Recent News & Updates

Immatics launches $110M stock offering

Oct 10

Recent updates

Immatics launches $110M stock offering

Oct 10

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Jul 19

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Jan 29
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Dec 16
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

Shareholder Returns

IMTXUS BiotechsUS Market
7D5.3%-0.8%1.7%
1Y-10.4%4.4%-9.6%

Return vs Industry: IMTX underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: IMTX matched the US Market which returned -9.6% over the past year.

Price Volatility

Is IMTX's price volatile compared to industry and market?
IMTX volatility
IMTX Average Weekly Movement7.3%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: IMTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IMTX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a382Harpreet Singhhttps://www.immatics.com

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell.

Immatics N.V. Fundamentals Summary

How do Immatics's earnings and revenue compare to its market cap?
IMTX fundamental statistics
Market CapUS$635.73m
Earnings (TTM)US$36.66m
Revenue (TTM)US$162.92m

17.3x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMTX income statement (TTM)
Revenue€150.91m
Cost of Revenue€101.89m
Gross Profit€49.02m
Other Expenses€15.06m
Earnings€33.96m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.45
Gross Margin32.48%
Net Profit Margin22.50%
Debt/Equity Ratio0%

How did IMTX perform over the long term?

See historical performance and comparison